Please assess the completion status of the following clinical trial:

Trial Title: Dose Tapering Study of Adalimumab in Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants must have a clinical or histological diagnosis of chronic plaque-type psoriasis for at least 6 months prior to inclusion~2. Participants must have a stable disease during maintenance on adalimumab (absolute PASI \< 3)~3. Participants are not allowed to use topical steroids from 7 days before randomization until the end of the study (week 48).~4. Participants must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study~Exclusion Criteria:~1. Participants who have currently a predominant nonplaque form of psoriasis~2. Participants who are pregnant, nursing or planning a pregnancy while enrolled in the study or within 12 weeks after receiving the last administration of study intervention~3. Participants who are unable or unwilling to undergo multiple venapunctures~4. Participants who are treated according to a different dosing schedule than standard dosing of adalimumab (regular dose regimen every 2 weeks; 40 mg)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard dosing group (Type: ACTIVE_COMPARATOR): Patients will continue to receive adalimumab according to the standard dosing schedule.
- Dose tapering group (Type: EXPERIMENTAL): Adalimumab dosing frequency will be lowered in patients who have supratherapeutic serum trough levels of adalimumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).